Beactica Therapeutics to present update on LSD1 programme at the AACR Annual Meeting 2023

/PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its LSD1 programme has been selected for a poster...

Related Keywords

Orlando ,Florida ,United States ,Orange County Convention Center ,Sweden ,Stockholm ,Swedish ,American ,Konrad Koehler ,Drug Administration ,American Association For Cancer Research Annual Meeting ,American Association For Cancer Research ,American Association ,Cancer Research ,Annual Meeting ,Sunday April ,Abstract Presentation Number ,Orphan Drug Designation ,Beactica Therapeutics Ab ,